Biologics Outsourcing Services Market Size, Share, Opportunities, And Trends By Service Type (Drug Development, Manufacturing, Regulatory & Compliance, Clinical Research), By Molecule Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell & Gene Therapies), By End-User (Pharmaceutical Companies, Biotechnology Firms, CROs, Academic Institutions), And By Geography - Forecasts From 2025 To 2030

Biologics Outsourcing Services Market Size:

The biologics outsourcing services market will grow at a CAGR of 11.37% to be valued at US$35.89 billion in 2030 from US$20.945 billion in 2025.

Biologics are essentially the drugs procured from living organisms or those which consist of the components of living organisms. These drugs are further used for the treatment of a range of diseases such as chronic diseases, cancer, cardiovascular diseases, etc. They are composed of sugar, proteins, and nucleic acid. When compared to small molecule drugs, biologics are much costlier but provide better results to the patient.

Biologics Outsourcing Services Market Growth Drivers:

A major reason for the growth of this market is the growing need for Research and Development in the biologics outsourcing market and the advancement in biologic therapeutics.

Investment in research has increased rapidly. Globally, spending on research and development has increased in the past two decades. Every year the pharmaceutical industry develops a new variety of drugs. Data from the UNESCO Institute for Statistics (UIS) suggests that global spending on research and development has reached almost US$ 1.7 trillion. According to the World Bank, East Asia and Pacific expenditure on research and development as a percentage of GDP accounts for 2.51 percent. The share of Korea remains the highest (4.81 percent) followed by Japan (3.26 percent) and China (2.19 percent) in the year 2018. In the US alone, pharmaceutical commerce spent $ 83 billion on Research and Development in 2019. According to UNESCO, North America and Western Europe spend the highest on R&D, followed by East Asia, South America, and Africa. Switzerland is the third-largest country to spend on R&D. With an ever-increasing expenditure on research and development, the global biologics outsourcing market is expected to grow.

Biologic therapeutics are considered to be the medicinal solutions of the future. Many countries are working on the advancement of co-formulation strategies to establish biological therapeutics. This will increase compliance, convenience, and accordance.

The investment and competition in the biologics outsourcing market are expected to drive the demand for this market in the forecast period.

Several players are making massive investments in the biologics outsourcing market across the world. The biologic outsourcing market is segmented into North America, Europe, South America, and the Asia Pacific region. North America is leading the biological outsourcing market. Owing to a huge investment, wide population, and low-cost drug manufacturing, the Asia-Pacific region prevails as the fastest-growing biologics outsourcing market. With rapidly increasing investment, the European market is also expected to expand.

There's rapidly growing competition in the biologic outsourcing industries. The US owns the largest biologics market. Countries like India and China are providing a competitive edge in terms of lower prices and costs. Some of the leading competitors are Eurofins Scientific SE, WuXi AppTec, Lonza Group Ltd, SGS SA, Etc.

The rising chronic diseases, aging population, and investment are likely to accelerate the global biologics outsourcing market.

According to the world health organization, globally 41 million people die due to chronic diseases. A major proportion of these deaths are accounted to cardiovascular diseases. It claims 17.9 million lives annually, followed by cancer (9 million lives annually), respiratory diseases (3.9 million lives annually), and diabetes (1.6 million lives annually). According to the world health organization, “The number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries.” According to the National Institute on Aging, approximately 79 percent of people, aged above 70 years, possess at least one of the seven chronic diseases- heart problems, diabetes, cancer, hypertension, stroke, arthritis, and respiratory disease. The growing number of people suffering from these chronic ailments is expected to drive the biologic outsourcing market. Biologic drugs are considered to be very useful when it comes to treating such diseases. Moreover, companies are constantly investing in the research and development sector. Biocon Biologics is all set to invest Rupees 555 crores in 2021. Novartis AG, in Singapore, invested USD $700 million in its biologics sector and Squibb invested USD $900 million in 2019.

The global biologics outsourcing services market report provides an in-depth analysis of the industry, delivering strategic insights backed by data-driven forecasts and comprehensive evaluations. This regularly updated report empowers decision-makers with actionable intelligence on market trends, growth opportunities, and competitive dynamics. It examines demand across key biologics outsourcing services categories, exploring cutting-edge service types and end-users. The report also assesses technological advancements, regulatory frameworks, government policies, and macroeconomic factors, offering a holistic market perspective.

Biologics Outsourcing Services Market Segmentations:

Biologics Outsourcing Services Market Segmentation by service type:

The market is analyzed by the following service types:

• Drug Development Services:
  • Cell Line Development
  • Process Optimization
  • Analytical Testing
• Manufacturing Services:
  • Drug Substance Manufacturing
  • Fill/Finish Operations
  • Biosimilar Production
  • Regulatory & Compliance Services
• Clinical Research Services:
  • Preclinical Studies
  • Phase I-IV Trials

Biologics Outsourcing Services Market Segmentation by molecule type:

The report analyzes the market by molecule type:

• Monoclonal Antibodies (mAbs)
• Recombinant Proteins
• Vaccines
• Cell & Gene Therapies
• Others

Biologics Outsourcing Services Market Segmentation by end-user:

The market is segmented by end-user:

• Pharmaceutical Companies
• Biotechnology Firms
• Contract Research Organizations (CROs)
• Academic & Research Institutions

Biologics Outsourcing Services Market Segmentation by regions:

The study also analyzed the biologics outsourcing services market into the following regions, with country-level forecasts and analysis as below:

• North America (US, Canada, and Mexico)
• South America (Brazil, Argentina, and Others)
• Europe (Germany, UK, France, Spain, and Others
• Middle East and Africa (Saudi Arabia, UAE, and Others)
• Asia Pacific (China, Japan, India, South Korea, Thailand, Indonesia, and Others)

Biologics Outsourcing Services Market Competitive Landscape:

The global biologics outsourcing services market features key players such as Lonza Group AG, WuXi Biologics, Catalent Inc., Samsung Biologics Co., Ltd., Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, AbbVie Contract Manufacturing, Thermo Fisher Scientific Inc., AGC Biologics, and Recipharm AB. 

Biologics Outsourcing Services Market Report Coverage:

This report provides extensive coverage as explained in the points below:

• Biologics Outsourcing Services Market Size, Forecasts, and Trends by Service Type: Historical revenue data and analysis focusing on adoption based on service type. 
• Biologics Outsourcing Services Market Size, Forecasts, and Trends by Molecule Type and End-User. 
• The Biologics outsourcing services market is also analyzed across different regions, with historical data, regional share, attractiveness, and opportunity of these solutions in different countries. The growth prospects and key players operating in these markets. The section also dwells on the macro factors, economic scenario, and other complementary factors aiding in market growth. 
• Market dynamics: The section details the market growth factors, restraints, and opportunities in the market. The segment also presents a complete market scenario with the help of Porter’s five forces model. 
• Competitive Intelligence: A thorough investigation of the competitive structure of the market presented through a proprietary vendor matrix model, market share analysis of key players, insights on strategies of key players, and recent major developments undertaken by the companies to gain a competitive edge. 
• Research methodology: The assumptions and sources that were considered to arrive at the final market estimates. Additionally, how our model is refined to ensure the most significant factors are taken into consideration with the proper hypothesis and bottom-up and top-down approaches enhance the reliability of forecasts further strengthening the trustworthiness of the numbers being presented. 

How this report is helpful to you and reasons for the purchase?

• The report provides a strategic outlook of the biologics outsourcing services market to the decision-makers, analysts, and other stakeholders in the easy-to-read format for making informed decisions.
• The charts, tables, and figures make it easy for the executives to gain valuable insights while skimming the report. 
• Analyst support through calls and emails for timely clarification and incorporating additional requests. 
• Option of presentation or doc format with the estimates file to take care of diverse requirements. 
• 15% FREE customization with all our reports to help cater to additional requirements with significant cost savings. 
• Option of purchasing specific segments of the study, including opting for summary reports or just the estimates file. 

Biologics Outsourcing Services Market Scope:

Report Metric	Details
Biologics Outsourcing Services Market Size in 2025	US$20.945 billion
Biologics Outsourcing Services Market Size in 2030	US$35.89 billion
Growth Rate	CAGR of 11.37%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Service Type Molecule Type End-User Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Biologics Outsourcing Services Market	Lonza Group AG WuXi Biologics Catalent, Inc. Samsung Biologics Co., Ltd. Boehringer Ingelheim BioXcellence
Customization Scope	Free report customization with purchase

 

Our Best-Performing Industry Reports:

• Orthobiologics Market
• Biologics Contract Development Market
• Biologics Contract Development And Manufacturing Organization (CDMO) Market

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. BIOLOGICS OUTSOURCING SERVICES MARKET BY SERVICE TYPE

5.1. Introduction

5.2. Drug Development Services:

5.2.1. Cell Line Development

5.2.2. Process Optimization

5.2.3. Analytical Testing

5.3. Manufacturing Services:

5.3.1. Drug Substance Manufacturing

5.3.2. Fill/Finish Operations

5.3.3. Biosimilar Production

5.4. Regulatory & Compliance Services

5.5. Clinical Research Services:

5.5.1. Preclinical Studies

5.5.2. Phase I-IV Trials

6. BIOLOGICS OUTSOURCING SERVICES MARKET BY MOLECULE TYPE

6.1. Introduction

6.2. Monoclonal Antibodies (mAbs)

6.3. Recombinant Proteins

6.4. Vaccines

6.5. Cell & Gene Therapies

6.6. Others

7. BIOLOGICS OUTSOURCING SERVICES MARKET BY END-USER

7.1. Introduction

7.2. Pharmaceutical Companies

7.3. Biotechnology Firms

7.4. Contract Research Organizations (CROs)

7.5. Academic & Research Institutions

8. BIOLOGICS OUTSOURCING SERVICES MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Thailand

8.6.7. Indonesia

8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Lonza Group AG

10.2. WuXi Biologics

10.3. Catalent, Inc.

10.4. Samsung Biologics Co., Ltd.

10.5. Boehringer Ingelheim BioXcellence

10.6. Fujifilm Diosynth Biotechnologies

10.7. AbbVie Contract Manufacturing

10.8. Thermo Fisher Scientific Inc.

10.9. AGC Biologics

10.10. Recipharm AB

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Lonza Group AG

WuXi Biologics

Catalent, Inc.

Samsung Biologics Co., Ltd.

Boehringer Ingelheim BioXcellence

Fujifilm Diosynth Biotechnologies

AbbVie Contract Manufacturing

Thermo Fisher Scientific Inc.

AGC Biologics

Recipharm AB